Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

MLA

Palmieri, Raffaele, et al. “Randomized Phase 1 Study of Sequential (‘primed’) vs. Concurrent Decitabine in Combination with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm.” Leukemia & Lymphoma, vol. 61, no. 7, July 2020, pp. 1728–31. EBSCOhost, https://doi.org/10.1080/10428194.2020.1728754.

APA

Palmieri, R., Buckley, S. A., Othus, M., Halpern, A. B., Percival, M.-E. M., Scott, B. L., Hendrie, P. C., Becker, P. S., Oehler, V. G., Estey, E. H., & Walter, R. B. (2020). Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Leukemia & Lymphoma, 61(7), 1728–1731. https://doi.org/10.1080/10428194.2020.1728754

Chicago

Palmieri, Raffaele, Sarah A Buckley, Megan Othus, Anna B Halpern, Mary-Elizabeth M Percival, Bart L Scott, Paul C Hendrie, et al. 2020. “Randomized Phase 1 Study of Sequential (‘primed’) vs. Concurrent Decitabine in Combination with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm.” Leukemia & Lymphoma 61 (7): 1728–31. doi:10.1080/10428194.2020.1728754.